Aurora, ILLINOIS10 Active Studies

Prostate Cancer Clinical Trials in Aurora, ILLINOIS

Find 10 actively recruiting prostate cancer clinical trials in Aurora, ILLINOIS. Connect with local research sites and explore new treatment options.

10
Active Trials
8
Sponsors
6,016
Enrolling

Recruiting Prostate Cancer Studies in Aurora

RecruitingAurora, ILLINOISNCT06136624

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) ...

1,310 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingAurora, ILLINOISNCT02861573

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will b...

1,200 participants
Merck Sharp & Dohme LLC
View Study Details
RecruitingAurora, ILLINOISNCT06764485

A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer....

960 participants
Celgene
View Study Details
RecruitingAurora, ILLINOISNCT02960022

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study

The purpose of this study is to collect long term safety data in subjects who are continuing to derive clinical benefit from treatment with Enzalutamide from the subjects participation in an enzalutam...

900 participants
Astellas Pharma Global Development, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT05803941

Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 17...

700 participants
Novartis Pharmaceuticals
View Study Details
RecruitingAurora, ILLINOISNCT04464226

Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer

The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation...

402 participants
Bayer
View Study Details
RecruitingAurora, ILLINOISNCT06785636

Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617

This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with Abiraterone acetate, Olaparib or 177Lu-PSMA-617 in patients with metastatic castration...

252 participants
Pathos AI, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT05682443

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled. The ...

141 participants
OncoC4, Inc.
View Study Details
RecruitingAurora, ILLINOISNCT04038502

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

This is an unblinded, randomized clinical study comparing the efficacy of DNA damaging chemotherapy using carboplatin, to standard of care therapy for patients who have metastatic castrate resistant p...

100 participants
VA Office of Research and Development
View Study Details
RecruitingAurora, ILLINOISNCT05011383

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermitt...

51 participants
VA Office of Research and Development
View Study Details

About Prostate Cancer Clinical Trials in Aurora

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 10 prostate cancer clinical trials recruiting participants in Aurora, ILLINOIS. These studies are seeking a combined 6,016 participants. Research is being sponsored by Merck Sharp & Dohme LLC, Celgene, Astellas Pharma Global Development, Inc. and 5 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Aurora — FAQ

Are there prostate cancer clinical trials in Aurora?

Yes, there are 10 prostate cancer clinical trials currently recruiting in Aurora, ILLINOIS. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Aurora?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Aurora research site will contact you about next steps.

Are clinical trials in Aurora free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Aurora studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 10 active trials in Aurora are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated March 2, 2026 from ClinicalTrials.gov